Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (CBIO) on October 15, 2019, reporting events occurring on October 9, 2019. The filing discloses the entry into a Material Definitive Agreement with Catalent Indiana, LLC. Note: The request metadata references "Gyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
This filing is a Current Report regarding a contractual agreement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of a Clinical Supply Agreement with Catalent Indiana, LLC., effective October 4, 2019. Under this agreement, Catalent will produce formulated drug products and provide related development and regulatory services for Catalyst Biosciences using company-supplied materials.
Guidance, Outlook, and Contract Terms
- Term: The initial term is three years, extendable for successive twelve-month periods unless terminated with 90 days' prior notice.
- Termination: Either party may terminate for material uncured breach or bankruptcy. Catalyst Biosciences may terminate for convenience with 30 days' prior written notice. Termination is also permitted if a party fails to perform due to reasons beyond reasonable control (e.g., technical or scientific reasons).
- Costs: If Catalyst Biosciences cancels or reschedules a project plan outside agreed parameters, it must pay a portion of Catalent's costs less mitigated fees.
- Intellectual Property: Catalyst Biosciences owns IP specifically related to the Products (composition and use). Catalent owns IP resulting from its performance of services.
Investor Verification Checklist
- Verify the specific project plans and product parameters to be incorporated into the Clinical Supply Agreement, as these are not detailed in the 8-K summary.
- Review the full text of Exhibit 10.1 (Clinical Supply Agreement) for redacted confidential portions regarding specific cost structures and fees.
- Confirm the impact of this agreement on the company's cash burn rate and future capital requirements for clinical supply.
- Monitor for any future filings regarding the execution of specific project plans under this master agreement.